{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T11:16:23Z","timestamp":1759058183067,"version":"3.40.4"},"reference-count":42,"publisher":"Japanese Society for the Study of Xenobiotics","issue":"1","license":[{"start":{"date-parts":[[2014,1,1]],"date-time":"2014-01-01T00:00:00Z","timestamp":1388534400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Drug Metabolism and Pharmacokinetics"],"published-print":{"date-parts":[[2014]]},"DOI":"10.2133\/dmpk.dmpk-13-rg-044","type":"journal-article","created":{"date-parts":[[2013,7,15]],"date-time":"2013-07-15T22:58:17Z","timestamp":1373929097000},"page":"52-60","source":"Crossref","is-referenced-by-count":16,"title":["In Silieo Study on the Inhibitory Interaction of Drugs with Wild-type CYP2D6.1 and the Natural Variant CYP2D6.17"],"prefix":"10.2133","volume":"29","author":[{"given":"Koichi","family":"Handa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Izumi","family":"Nakagome","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noriyuki","family":"Yamaotsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroaki","family":"Gouda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuichi","family":"Hirono","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"900","reference":[{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0005","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1081\/DMR-120001392","article-title":"Summary of information on human CYP enzymes: human P450 metabolism data","volume":"34","author":"Rendic","year":"2002","journal-title":"Drug Metab. Rev."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0010","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/S0022-3565(25)22379-5","article-title":"Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians","volume":"270","author":"Shimada","year":"1994","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.2165\/11318030-000000000-00000","article-title":"Polymorphism of human cytochrome P450 2D6 and its clinical significance: Part I","volume":"48","author":"Zhou","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0020","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1046\/j.1365-2125.2000.00209.x","article-title":"Frequencies of CYP2D6 mutant alleles in a normal Japanese population and metabolic activity of dextromethorphan O-demethylation in different CYP2D6 genotypes","volume":"50","author":"Kubota","year":"2000","journal-title":"Br. J. Clin. Pharmacol"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0025","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1046\/j.0306-5251.2001.01437.x","article-title":"Plasma concentrations of haloperidol are related to CYP2D6 genotype at low, but not high doses of haloperidol in Korean schizophrenic patients","volume":"52","author":"Roh","year":"2001","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0030","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1007\/s10038-006-0034-0","article-title":"The high prevalence of the poor and ultrarapid metabolite alleles of CYP2D6, CYP2C9, CYP2C19, CYP3A4, and CYP3A5 in Taiwanese population","volume":"51","author":"Liou","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0035","first-page":"1780","article-title":"Genetic polymorphisms of CYP2D6 in Chinese mainland","volume":"115","author":"Ji","year":"2002","journal-title":"Chin. Med. J."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0040","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/S0006-291X(02)00328-5","article-title":"CYP2D6.10 present in human liver microsomes shows low catalytic activity and thermal stability","volume":"293","author":"Nakamura","year":"2002","journal-title":"Biochem. Biophys. Res. Commun"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0045","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1097\/00008571-200108000-00004","article-title":"Analysis of the CYP2D6 gene polymorphism and enzyme activity in African-Americans in southern California","volume":"11","author":"Wan","year":"2001","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0050","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1046\/j.1365-2125.1996.00489.x","article-title":"A novel mutant variant of the CYP2D6 gene (CYP2D6*17) common in a black African population: association with diminished debrisoquine hydroxylase activity","volume":"42","author":"Masimirembwa","year":"1996","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0055","first-page":"441","article-title":"Frequent distribution of ultrarapid metabolizers of debrisoquine in an ethiopian population carrying duplicated and multiduplicated functional CYP2D6 alleles","volume":"278","author":"Aklillu","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0060","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/00008571-199912000-00005","article-title":"Decreased capacity for debrisoquine metabolism among black Tanzanians: analyses of the CYP2D6 genotype and phenotype","volume":"9","author":"Wennerholm","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0065","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1046\/j.1365-2125.1999.00861.x","article-title":"CYP2D6 polymorphism in a Gabonese population: contribution of the CYP2D6*2 and CYP2D6*17 alleles to the high prevalence of the intermediate metabolic phenotype","volume":"47","author":"Panserat","year":"1999","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0070","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1097\/00008571-199912000-00006","article-title":"Analysis of the CYP2D6 gene mutations and their consequences for enzyme function in a West African population","volume":"9","author":"Griese","year":"1999","journal-title":"Pharmacogenetics"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0075","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1067\/mcp.2002.120239","article-title":"The African-specific CYP2D617 allele encodes an enzyme with changed substrate specificity","volume":"71","author":"Wennerholm","year":"2002","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0080","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1124\/dmd.30.5.595","article-title":"Characterization of cytochrome P450 2D6.1 (CYP2D6.1), CYP2D6.2, and CYP2D6.17 activities toward model CYP2D6 substrates dextromethorphan, bufuralol, and debrisoquine","volume":"30","author":"Marcucci","year":"2002","journal-title":"Drug Metab. Dispos"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0085","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.tiv.2005.04.001","article-title":"Substrate specific metabolism by polymorphic cytochrome P450 2D6 alleles","volume":"19","author":"Bogni","year":"2005","journal-title":"Toxicol. In Vitro"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0090","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/sj.tpj.6500378","article-title":"CYP2D6 genetic variation in healthy adults and psychiatric African-American subjects: implications for clinical practice and genetic testing","volume":"6","author":"Cai","year":"2006","journal-title":"Pharmacogenomics J."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0095","unstructured":"ICH E5 (R1): Ethnic Factors in the Acceptability of Foreign Clinical Data, February 1998."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0100","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1081\/BIP-120014564","article-title":"Bridging studies in clinical development","volume":"12","author":"Liu","year":"2002","journal-title":"J. Biopharm. Stat."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0105","first-page":"381","article-title":"Global drug development based on ICH-E5 guideline","volume":"15","author":"Matsui","year":"2000","journal-title":"Xenobic Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0110","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1081\/BIP-200040836","article-title":"A two-stage design for bridging studies","volume":"15","author":"Hsiao","year":"2005","journal-title":"J. Biopharm. Stat."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0115","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1081\/BIP-120014566","article-title":"Practical issues and observations on the use of foreign clinical data in drug development","volume":"12","author":"Goto","year":"2002","journal-title":"J. Biopharm. Stat."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0120","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1081\/BIP-120024210","article-title":"A group sequential approach to evaluation of bridging studies","volume":"13","author":"Hsiao","year":"2003","journal-title":"J. Biopharm. Stat."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0125","doi-asserted-by":"crossref","first-page":"80","DOI":"10.5414\/CPP38080","article-title":"Necessity and requirements of bridging studies and their present status in Japan","volume":"38","author":"Naito","year":"2000","journal-title":"Int. J. Clin. Pharmacol. Ther."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0130","doi-asserted-by":"crossref","first-page":"121","DOI":"10.4103\/2229-3485.86874","article-title":"Implications of ICH-E5: Assessment of drug's sensitivity to ethnic factors and necessity of a bridging study for global drug development","volume":"2","author":"Gupta","year":"2011","journal-title":"Perspect. Clin. Res."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0135","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.1124\/dmd.107.015354","article-title":"Comparative metabolic capabilities and inhibitory profiles of CYP2D6.1, CYP2D6.10, and CYP2D6.17","volume":"35","author":"Shen","year":"2007","journal-title":"Drug Metab. Dispos"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0140","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1124\/dmd.110.036780","article-title":"Comparison of the inhibitory profiles of itraconazole and cimetidine in cytochrome P450 3A4 genetic variants","volume":"39","author":"Akiyoshi","year":"2011","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0145","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1124\/mol.52.6.1034","article-title":"A combination of mutations in the CYP2D6*17 (CYP2D6Z) allele causes alterations in enzyme function","volume":"52","author":"Oscarson","year":"1997","journal-title":"Mol. Pharmacol."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0150","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1016\/j.phymed.2012.01.005","article-title":"Molecular docking and enzyme kinetic studies of dihydrotanshinone on metabolism of a model CYP2D6 probe substrate in human liver microsomes","volume":"19","author":"Zhou","year":"2012","journal-title":"Phytomedicine"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0155","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.2174\/138920112800958779","article-title":"Pharmacophore, QSAR, and binding mode studies of substrates of human cytochrome P450 2D6 (CYP2D6) using molecular docking and virtual mutations and an application to Chinese herbal medicine screening","volume":"13","author":"Mo","year":"2011","journal-title":"Curr. Pharm. Biotechnol."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0160","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1124\/dmd.111.041210","article-title":"Prediction of CYP2D6 drug interactions from in vitro data: evidence for substrate-dependent inhibition","volume":"40","author":"VandenBrink","year":"2012","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0165","doi-asserted-by":"crossref","first-page":"36","DOI":"10.2174\/138620712798280826","article-title":"Ligand- and protein-based modeling studies of the inhibitors of human cytochrome P450 2D6 and a virtual screening for potential inhibitors from the Chinese herbal medicine, Scutellaria baicalensis (Huangqin, Baikal Skullcap)","volume":"15","author":"Mo","year":"2012","journal-title":"Comb. Chem. High Throughput Screen."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0170","doi-asserted-by":"crossref","first-page":"7078","DOI":"10.1021\/jp1008994","article-title":"Brain chemistry: how does P450 catalyze the O-demethylation reaction of 5-methoxytryptamine to yield serotonin?","volume":"114","author":"Schyman","year":"2010","journal-title":"J. Phys. Chem. B"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0175","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1124\/dmd.108.020776","article-title":"Novel binding mode of the acidic CYP2D6 substrates pactimibe and its metabolite R-125528","volume":"36","author":"Kotsuma","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0180","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.jmgm.2007.07.004","article-title":"Analysis of CYP2D6 substrate interactions by computational methods","volume":"26","author":"Ito","year":"2008","journal-title":"J. Mol. Graph. Model."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0185","first-page":"38617","article-title":"Why is quinidine an inhibitor of cytochrome P450 2D6?","volume":"280","author":"McLaughlin","year":"2005","journal-title":"The role of key activesite residues in quinidine binding. J. Biol. Chem."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0190","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0006-2952(02)01351-5","article-title":"The molecular and enzyme kinetic basis for the diminished activity of the cytochrome P450 2D6.17 (CYP2D6.17) variant. Potential implications for CYP2D6 phenotyping studies and the clinical use of CYP2D6 substrate drugs in some African populations","volume":"64","author":"Bapiro","year":"2002","journal-title":"Biochem. Pharmacol"},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0195","doi-asserted-by":"crossref","first-page":"7614","DOI":"10.1074\/jbc.M511232200","article-title":"Crystal structure of human cytochrome P450 2D6","volume":"281","author":"Rowland","year":"2006","journal-title":"J. Biol. Chem."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0200","doi-asserted-by":"crossref","first-page":"10834","DOI":"10.1074\/jbc.M111.307918","article-title":"Crystal structure of human cytochrome P450 2D6 with prinomastat bound","volume":"287","author":"Wang","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0205","doi-asserted-by":"crossref","first-page":"4805","DOI":"10.1021\/jm060522a","article-title":"Accurate prediction of the relative potencies of members of a series of kinase inhibitors using molecular docking and MM-GBSA scoring","volume":"49","author":"Lyne","year":"2006","journal-title":"J. Med. Chem."},{"key":"10.2133\/dmpk.DMPK-13-RG-044_bb0210","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1002\/jcc.21859","article-title":"Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime\/MM-GBSA calculation","volume":"32","author":"Du","year":"2011","journal-title":"J. Comput. Chem"}],"container-title":["Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715302950?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S1347436715302950?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T13:12:08Z","timestamp":1746018728000},"score":1,"resource":{"primary":{"URL":"http:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1347436715302950"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2014]]}},"alternative-id":["S1347436715302950"],"URL":"https:\/\/doi.org\/10.2133\/dmpk.dmpk-13-rg-044","relation":{},"ISSN":["1347-4367"],"issn-type":[{"type":"print","value":"1347-4367"}],"subject":[],"published":{"date-parts":[[2014]]}}}